Literature DB >> 32383815

A single supratentorial high-grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival.

Juliane Bremer1,2, Raimund Kottke3, Pascal D Johann4,5,6, Katja von Hoff7, Pierluigi Brazzola8, Michael A Grotzer9, Marcel Kool4,5,10, Elisabeth Rushing1, Nicolas U Gerber9.   

Abstract

Here, we present a patient with high-grade neuroepithelial tumors with mutations in the BCL6 corepressor BCOR (HGNET-BCOR), a rare, highly malignant brain tumor with poor prognosis. The patient underwent gross total tumor resection (GTR), high-dose chemotherapy, and, after local relapse, GTR, proton radiation, and chemotherapy. After a 7.5 year-long complete remission, the tumor recurred locally, was treated by GTR, and responded to temozolomide treatment. In addition to an internal tandem duplication in BCOR common to the majority of HGNET-BCOR cases, molecular analysis revealed a second BCOR mutation in this tumor: a frame shift mutation. The combination of these mutations was associated with relatively low BCOR expression compared to other HGNET-BCOR cases.
© 2020 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.

Entities:  

Keywords:  BCOR; HGNET-BCOR; brain tumor; high-grade neuroepithelial tumor

Year:  2020        PMID: 32383815     DOI: 10.1002/pbc.28384

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

1.  Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a BCOR Internal Tandem Duplication.

Authors:  L Cardoen; A Tauziède-Espariat; V Dangouloff-Ros; S Moalla; N Nicolas; C-J Roux; Y Bouchoucha; F Bourdeaut; K Beccaria; S Bolle; G Pierron; C Dufour; F Doz; N Boddaert; H J Brisse
Journal:  AJNR Am J Neuroradiol       Date:  2021-12-09       Impact factor: 3.825

2.  The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of "CNS tumors with BCOR internal tandem duplication".

Authors:  Arnault Tauziède-Espariat; Gaëlle Pierron; Aurore Siegfried; Delphine Guillemot; Emmanuelle Uro-Coste; Yvan Nicaise; David Castel; Isabelle Catalaa; Delphine Larrieu-Ciron; Patrick Chaynes; Amaury de Barros; Julien Nicolau; Albane Gareton; Emmanuèle Lechapt; Fabrice Chrétien; Franck Bourdeaut; François Doz; Yassine Bouchoucha; Jacques Grill; Kévin Beccaria; Nathalie Boddaert; Raphaël Saffroy; Mélanie Pagès; Pascale Varlet
Journal:  Acta Neuropathol Commun       Date:  2020-11-02       Impact factor: 7.801

3.  Intra- and extra-cranial BCOR-ITD tumours are separate entities within the BCOR-rearranged family.

Authors:  Yassine Bouchoucha; Arnault Tauziède-Espariat; Arnaud Gauthier; Gaëlle Pierron; François Doz; Delphine Guillemot; Dorian Bochaton; Julien Vibert; Matthieu Carton; Sarah Watson; Sandrine Grossetête; Chloé Quignot; Daniel Orbach; Nadège Corradini; Gudrun Schleiermacher; Franck Bourdeaut; Marie Simbozel; Christelle Dufour; Véronique Minard-Colin; Mehdi Brahmi; Franck Tirode; Daniel Pissaloux; Marie Karanian; Marie-Christine Machet; Julien Masliah-Planchon; Olivier Delattre; Liesbeth Cardoen
Journal:  J Pathol Clin Res       Date:  2022-02-17

4.  Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.

Authors:  Arnault Tauziède-Espariat; Aurore Siegfried; Emmanuelle Uro-Coste; Pascale Varlet; Yvan Nicaise; Thomas Kergrohen; Philipp Sievers; Alexandre Vasiljevic; Alexandre Roux; Edouard Dezamis; Chiara Benevello; Marie-Christine Machet; Sophie Michalak; Chloe Puiseux; Francisco Llamas-Gutierrez; Pierre Leblond; Franck Bourdeaut; Jacques Grill; Christelle Dufour; Léa Guerrini-Rousseau; Samuel Abbou; Volodia Dangouloff-Ros; Nathalie Boddaert; Raphaël Saffroy; Lauren Hasty; Ellen Wahler; Mélanie Pagès; Felipe Andreiuolo; Emmanuèle Lechapt; Fabrice Chrétien; Thomas Blauwblomme; Kévin Beccaria; Johan Pallud; Stéphanie Puget
Journal:  Acta Neuropathol Commun       Date:  2021-08-13       Impact factor: 7.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.